Literature DB >> 28087388

Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis.

Paula Saavedra-García1, Katie Nichols1, Zimam Mahmud1, Lavender Yuen-Nam Fan1, Eric W-F Lam2.   

Abstract

Obesity and cachexia represent divergent states of nutritional and metabolic imbalance but both are intimately linked to cancer. There is an extensive overlap in their signalling pathways and molecular components involved such as fatty acids (FAs), which likely play a crucial role in cancer. Forkhead box (FOX) proteins are responsible of a wide range of transcriptional programmes during normal development, and the FOXO3-FOXM1 axis is associated with cancer initiation, progression and drug resistance. Free fatty acids (FFAs), FA synthesis and β-oxidation are associated with cancer development and progression. Meanwhile, insulin and some adipokines, that are up-regulated by FAs, are also involved in cancer development and poor prognosis. In this review, we discuss the role of FA metabolism in cancer and how FA metabolism integrates with the FOXO3-FOXM1 axis. These new insights may provide leads to better cancer diagnostics as well as strategies for tackling cancer development, progression and drug resistance.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Keywords:  AKT/PI3K pathway; Cancer; FOXM1; FOXO3; Fatty acids; Lipid metabolism

Mesh:

Substances:

Year:  2017        PMID: 28087388     DOI: 10.1016/j.mce.2017.01.012

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  9 in total

Review 1.  Drugging cancer metabolism: Expectations vs. reality.

Authors:  David C Montrose; Lorenzo Galluzzi
Journal:  Int Rev Cell Mol Biol       Date:  2019-07-29       Impact factor: 6.813

2.  USP39 facilitates breast cancer cell proliferation through stabilization of FOXM1.

Authors:  Zhenwang Zhang; Wu Liu; Xiajun Bao; Tian Sun; Jiawei Wang; Mengxi Li; Chao Liu
Journal:  Am J Cancer Res       Date:  2022-08-15       Impact factor: 5.942

3.  Assessment of YKL-40, lipid profile, antioxidant status, and some trace elements in benign and malignant breast proliferation.

Authors:  Eman M Shahy; Mona M Taha; Khadiga S Ibrahim
Journal:  Mol Biol Rep       Date:  2020-09-02       Impact factor: 2.316

4.  Prognostic nomogram integrated baseline serum lipids for patients with non-esophageal squamous cell carcinoma.

Authors:  Shulin Chen; Xiaohui Li; Xiaoyan Wen; Songguo Peng; Ning Xue; Shan Xing; Yijun Liu
Journal:  Ann Transl Med       Date:  2019-10

5.  Dataset of the human homologues and orthologues of lipid-metabolic genes identified as DAF-16 targets their roles in lipid and energy metabolism.

Authors:  Lavender Yuen-Nam Fan; Paula Saavedra-García; Eric Wing-Fai Lam
Journal:  Data Brief       Date:  2017-03-08

Review 6.  Microbiome-Microbial Metabolome-Cancer Cell Interactions in Breast Cancer-Familiar, but Unexplored.

Authors:  Edit Mikó; Tünde Kovács; Éva Sebő; Judit Tóth; Tamás Csonka; Gyula Ujlaki; Adrienn Sipos; Judit Szabó; Gábor Méhes; Péter Bai
Journal:  Cells       Date:  2019-03-29       Impact factor: 6.600

7.  Characterizing the breast cancer lipidome and its interaction with the tissue microbiota.

Authors:  Natasa Giallourou; Camilla Urbaniak; Scarlett Puebla-Barragan; Panagiotis A Vorkas; Jonathan R Swann; Gregor Reid
Journal:  Commun Biol       Date:  2021-10-27

8.  Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes.

Authors:  Trygve Lofterød; Elin S Mortensen; Hawa Nalwoga; Tom Wilsgaard; Hanne Frydenberg; Terje Risberg; Anne Elise Eggen; Anne McTiernan; Sura Aziz; Erik A Wist; Andreas Stensvold; Jon B Reitan; Lars A Akslen; Inger Thune
Journal:  BMC Cancer       Date:  2018-06-15       Impact factor: 4.430

Review 9.  A New Twist in Protein Kinase B/Akt Signaling: Role of Altered Cancer Cell Metabolism in Akt-Mediated Therapy Resistance.

Authors:  Isabell Götting; Verena Jendrossek; Johann Matschke
Journal:  Int J Mol Sci       Date:  2020-11-13       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.